Cancer Drugs

ProNAi Raises $12M Series C Financing To Expand Cancer StudiesThe cancer drug developer ProNAi Therapeutics Inc. Monday announced the closing of a Series C preferred financing round of more than $12 million with existing and new investors.
ProNAi To Present Phase II Clinical Data For New Cancer DrugProNAi Therapeutics Inc., a developer of drugs that target cancer by interfering with cancer cells' DNA, announced that data from its ongoing Phase II clinical study of its drug candidate PNT2258 will be presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans Dec. 7-10.
Truven Health Analytics Poll Finds Opinions Split Between Cancer Patients, Non-Patients On High-Cost DrugsCancer patients may have a different point of view on oncology drug decisions than non-patients, according to a new poll conducted by Truven Health Analytics.
WSU Researcher To Present Finding On New Non-Hodgkin's Lymphoma DrugsA Wayne State University researcher believes he has found a safer, more effective way to keep cancer cells from protecting themselves against tumor-killing drugs in cases of non-Hodgkin's lymphoma.
Best Winter Festivals In Metro Detroit
Thanksgiving Parade Guide

Watch & Listen